Skip to content
Buy This GLP
← Research
Safety

Do GLP-1 Drugs Weaken Your Bones?

Fracture findings differ by population and fracture site. Here is what pooled studies, a bone density trial and the Wegovy label found.

Editorial profile: Carla MedinaBuy This GLP Editorial Team5 min read
Pooled fracture risk in type 2 diabetes1.00.80The result is compatible with lower or higher fracture risk.0.47 to 1.36 — wide enough to contain both directions.

Findings on femoral fractures in older adults with type 2 diabetes concern a specific population and comparator. In those matched records, one-year rates were 0.3% for semaglutide versus 0.5% for a DPP-4 inhibitor, and 0.2% for tirzepatide versus 0.4% for a DPP-4 inhibitor in a separate cohort. The participants were at least 65 and had overweight or obesity. The study found an association and could not establish causation [1].

What does the Wegovy label say?

In the cardiovascular outcomes trial, hip or pelvic fractures were reported in 1.0% of women receiving Wegovy versus 0.2% with placebo (24 of 2,448 versus 5 of 2,424). Among adults aged 75 and older, they were reported in 2.4% versus 0.6% (17 of 703 versus 4 of 663) [2]. These groups can overlap. In a separate trial in adults with MASH, fractures were reported in 4.4% with Wegovy versus 3.3% with placebo [2]. That figure covers fractures generally, while the cardiovascular trial figures above describe hip and pelvic fractures.

What did the broader fracture evidence find?

A 2025 review of randomized trials in people with type 2 diabetes estimated a fracture risk ratio of 0.80 (95% CI 0.47 to 1.36). The interval leaves considerable uncertainty in both directions [3]. A later review that also included observational studies found no clear difference in overall fractures, with substantial variation between studies [4].

What happens to bone density?

A 52-week randomized study enrolled 64 adults at increased fracture risk. Once-weekly semaglutide showed no clear difference versus placebo on the primary bone formation marker. Bone density was lower at the lumbar spine and total hip, and a marker of bone breakdown was higher. The study was too small to determine whether fractures became more common[5].

If you have osteoporosis, a prior fracture or a high risk of falls, discuss your bone health with the clinician who manages your treatment.

Frequently asked

Do GLP-1 drugs increase fracture risk?
The pooled evidence does not establish an overall effect. The Wegovy label does report more hip or pelvic fractures in women and people aged 75 and older receiving Wegovy than in their respective placebo groups in the cardiovascular outcomes trial.
Does semaglutide lower bone density?
A small 52-week randomized trial in adults at increased fracture risk found lower bone density at the lumbar spine and total hip with semaglutide versus placebo. The trial did not establish what happens to fracture risk.

Sources

  1. [1] Chen HY, Wu JY, Chu YH, Chen TW, Huang CF (2026). Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes Osteoporosis International. PMID 42435064
  2. [2] Novo Nordisk (2026). Wegovy U.S. prescribing information DailyMed. Source
  3. [3] Tan Y, et al. (2025). Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis Acta Diabetologica. PMID 39985672
  4. [4] Beaudart C, et al. (2026). GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis Drugs. PMID 42730869
  5. [5] Hansen MS, et al. (2024). Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial EClinicalMedicine. PMID 38737002

More in Safety